RxDoctor Payments Data

Daniel Schrader, MD

Cardiovascular Disease · El Dorado, ARNPI 1689634982

Payments from drug & device makers

$361in general payments, 2019–2025

Across 23 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$109
  • Kowa Pharmaceuticals America, Inc.$95
  • Medtronic$50
  • Abbott$50
  • Philips North America LLC$29
  • Novartis$15
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$361100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$361 in reported general payments places this provider in the 10th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$477,052
Medicare patients
1,211
Services billed
5,668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban259$169,470
XareltoRivaroxaban149$99,111
EntrestoSacubitril/Valsartan101$79,742
FarxigaDapagliflozin Propanediol51$34,979
Ranolazine ErRanolazine194$18,058
LivaloPitavastatin Calcium13$10,436
DapagliflozinDapagliflozin Propanediol13$7,897
BrilintaTicagrelor12$5,435
Propafenone Hcl125$4,331
Dofetilide29$3,948
Amiodarone Hcl293$3,647
Dabigatran EtexilateDabigatran Etexilate Mesylate14$2,602
Pitavastatin Calcium22$2,338
SotalolSotalol Hcl132$2,041
Metoprolol Tartrate398$1,822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$109$99,111149 claims
NovartisEntresto$15$79,742101 claims
AstraZenecaFarxiga, Brilinta$13$40,41463 claims
Kowa Pharmaceuticals America, Inc.Livalo$95$10,43613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in El Dorado

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →